⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
ALMS News
Alumis Inc. Common Stock
Alumis to Participate in Upcoming September Investor Conferences
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Alumis Announces Topline Results from Envudeucitinib Phase 2b Trial in Systemic Lupus Erythematosus (SLE)
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Envudeucitinib Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
globenewswire.com
ALMS
Form 8-K
sec.gov
ALMS
Form 8-K
sec.gov
ALMS
Sotyktu’s Psoriatic Arthritis Launch Builds Gradually in Month Two as Rheumatologists Continue to Take Measured Approach to TYK2 Adoption, According to Spherix Global Insights
globenewswire.com
BMY
ABBV
UCB
ALMS
PFE